Contineum Therapeutics, Inc. — Income Charts
7 quarters of history · ending 2024-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$0
R&D↑+62.4% +$5M
$13M
D&A↑+102.7% +$38K
$75K
Operating Income↓-60.8% -$5M
$-13M
EBITDA↑+102.7% +$38K
$75K
Interest Expense
$0
Interest Income↑+41.2% +$738K
$3M
Other Income/Expense↑+5.6% +$2K
$-34K
Pretax Income↓-61.2% -$4M
$-10M
Tax Provision
$0
Net Income↓-64.2% -$4M
$-10M
Operating Margin
77.9%
Net Margin
83.1%
Effective Tax Rate↓-1.9pts
0.0%
ETR (Continuing Operations)
0.0%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
0.0%
ETR Foreign Differential (pp)
—
Operating Lease Cost
$200K
Revenue YoY Variation
-100.0%
Income YoY Variation
-60.8%
Revenue QoQ Variation
-100.0%
Income QoQ Variation↑+102.2pts
-18.5%